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Drug-induced liver injury (DILI) remains a significant clinical 
challenge and is the leading cause of acute liver failure in 
most countries. An aging population that uses more medica-
tions, a constant influx of newly developed drugs and a grow-
ing risk from unfamiliar herbal and dietary supplements will 
make DILI an increasing part of clinical practice. Currently, 
the most effective strategy for disease management is rapid 
identification, withholding the inciting agents, supportive 
care and having a firm understanding of the expected natu-
ral history. There are resources available to aid the clinician, 
including a new online “textbook” as well as causality as-
sessment tools, but a heightened awareness of risk and the 
disease’s varying phenotypes and good history-taking remain 
cornerstones to diagnosis. Looking ahead, growing registries 
of cases, pharmacoepidemiology studies and translational 
research into the mechanisms of injury may produce better 
diagnostic tools, markers for risk and disease, and preven-
tion and therapeutics. (Gut Liver 2016;10:27-36)
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INTRODUCTION
Among Western countries, drug-induced liver injury (DILI) 
remains the leading cause of acute liver failure (ALF).1 Thus 
DILI has profound implications on healthcare, affecting patient 
morbidity and mortality, healthcare expenditures, drug develop-
ment, and clinical practice. DILI remains one of the top reasons 
for drug withdrawal from the marketplace2 creating cost and 
medication availability ramifications that reach well beyond the 
individual having liver injury. The primary challenge in DILI 
care and research continues to be the rare, idiosyncratic and 
varied nature of disease presentation leading to difficult rec-
ognition and accrual of cases for study. This review will cover 
incidence, risk factors, clinical presentations and diagnostic 
strategies, and highlight some common culprit agents. Possible 
clinical advancements arising from current research will also 
be covered. Nonidiosyncratic liver injury such as that seen with 
acetaminophen will not be covered.
INCIDENCE
DILI incidence is difficult to determine but is commonly 
reported to be 1 in 10,000 to 1 in 100,000.3-5 Such estimates 
are undermined by under-reporting and varying diagnostic ac-
curacy of cases. Additionally, clinical trials are typically under-
powered to detect small incidences of toxicity.6 However, recent 
population based studies are shedding better light on the true 
incidence. A study from Iceland7 suggested an overall incidence 
of 19 per 100,000 and a much higher risk than expected for cer-
tain medications (e.g., 1 in 133 for azathioprine). This study was 
unique for its completeness of prescription data and vetting of 
DILI cases, and represented a rise in incidence compared to prior 
population based studies.4 Moreover incidence increased with 
age (Table 1), suggesting DILI incidence will rise in countries 
with aging populations. 
RISK FACTORS
At this time, there are only a few clinically useful risk fac-
tors. As mentioned, age increases the overall risk in part due to 
polypharmacy. A few individual medications, such as isoniazid 
(INH), flucloxacillin, halothane, amoxicillin-clavulanate, and 
nitrofurantoin carry increased risk with older age.8-12 There are 
some trends in the patterns of injury, with hepatocellular as well 
as autoimmune like injury being more common in females.3,13,14 
With respect to patients with chronic liver disease (CLD), it is 
hypothesized that this population would be at higher risk, given 
the inherent altered pharmacokinetics of medications metabo-
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lized by the liver.15 However, the data regarding this population 
is mixed and hindered by the vagaries of diagnosing DILI in 
patients with inherent competing causes for elevated liver bio-
chemistries (e.g., flares in autoimmune, viral, or alcoholic hepa-
titis).16-18 
While not yet clinically useful, other recently identified risk 
factors are beginning to elucidate the pathophysiology of DILI. 
Several human leukocyte antigen (HLA) serotypes have been 
identified as risk factors for DILI from specific agents (e.g., 
amoxicillin/clavulanate and flucloxacillin), suggesting an im-
portant immunologic component to DILI. Interestingly, drugs 
whose daily dose is 50 mg or more account for over 70% to 
80% of cases and there are several medications reported to 
cause DILI after a dosing increase. These data suggest idiosyn-
cratic DILI may have a dose dependent component similar to 
acetaminophen thus blurring the lines between nonidiosyncratic 
and idiosyncratic.19,20 Also lipophilicity has been shown to be 
a strong predictor of hepatotoxicity. In fact, when drugs have 
both a dosage over 100 mg per day as well as lipophilicity, there 
is a marked increased risk of toxicity, as shown by Chen et al.21
PRESENTATION, DIAGNOSIS AND OUTCOME
Clinical presentation will usually consist of nonspecific (nau-
sea, fatigue, and abdominal pain), and occasionally liver specific 
symptoms (jaundice, pruritus, encephalopathy, and ascites) in 
severe cases. Occasionally, rash, eosinophilia or a drug related 
eosinophilic systemic syndrome (DRESS) presentation will make 
drug hepatotoxicity obvious, but typically symptoms will not 
point specifically to DILI. Fever may be present with DILI as 
well as other competing diagnoses (gallstone disease and viral 
infection). Therefore, diagnosis is heavily reliant on obtaining a 
detailed history and careful selection of diagnostic tests. 
In the history, it is crucial to obtain the timing of exposure 
as precisely as possible, the biochemical pattern of injury, and 
a complete medication history, including prescribed, over the 
counter, and herbal or dietary supplements (HDS). Latencies 
for certain medications can be long, so patients will often not 
remember taking an agent let alone when they took it. Calling 
the patient’s pharmacy, interviewing family members and us-
ing memory cues can be quite helpful. Many times cases can be 
diagnosed by simply obtaining or retaking a meticulous history. 




Alk Phos÷Alk Phos ULN
(ULN, upper limit of normal)
R-ratios greater than 5 are considered hepatocellular injuries, 
2 to 5 mixed, and less than 2 cholestatic. While these cutoffs 
were set arbitrarily, they have proven useful clinically and in 
drug development. Determining the R-ratio can help decide the 
likelihood of DILI because agents will often have a propensity 
toward certain patterns of injury (Table 2). However, it is im-
portant to note that the pattern of injury can change over time, 
particularly from hepatocellular to cholestatic.23 Therefore, pa-
tients presenting late, may have moved through an undetected 
hepatocellular injury. Also, the calculated pattern of injury does 
not always match the histologic picture.24 The pattern of injury 
will also help narrow the list of competing diagnoses that need 
to be considered (e.g., cholestatic injury and gallstone disease, 
hepatocellular injury and viral infection). 
While not always necessary, a liver biopsy can be very help-
ful. As with the R-ratio there are certain histologic findings 
associated with particular agents (Table 3). The biopsy can be 
particularly helpful in ruling out other causes for liver injury13 
or pointing toward other etiologies such as autoimmune hepati-
tis (AIH) that often competes diagnostically with DILI. AIH diag-
nostic criteria include histology, and unlike DILI, AIH typically 
requires immunosuppression.25-27 One should also consider a bi-
opsy the longer the liver biochemistries stay elevated. DILI usu-
ally improves with time, so lack of resolution tends to erode the 
likelihood of DILI, and other etiologies need to be reconsidered. 
Generally, if the difference of the peak alanine aminotransferase 
(ALT) from the ULN in a hepatocellular injury does not reduce 
by greater than 50% by 60 days, a biopsy should be consid-
ered.28,29 For cholestatic injury, the cutoff is approximately 180 
days for a greater than 50% drop in alkaline phosphatase or 
bilirubin levels.30 
The Roussel Uclaf Causality Assessment Model (RUCAM) is 
a diagnostic scoring algorithm used to estimate the likelihood 
of DILI.23,28 It factors in variables such as the pattern of injury, 
timing, risk factors, competing causes, and rechallenge. Scores 
are grouped into five categories: “excluded” if score less than or 
equal to 0, “unlikely” if 1 to 2, “possible” if 3 to 5, “probable” if 
6 to 8, and “highly probable” if greater than 8. The main limit-
ing factor in its use is the ambiguity in defining some of the 
scoring variables. Alcohol use merits additional points, but the 
Table 1. Crude Annual Incidence of Drug Induced Liver Injury and 
Mean Prescription Rate in Iceland 
DILI per 100,000 Mean prescription rate
Overall 19.1 NA
Age, yr
  15–24   8.5 0.9
  25–39 12.6 1.2
  40–59 18.8 2.4
  60–69 32.6 4.8
  70–79 39.9 7.3
  80–106 41.0 9.3
DILI, drug induced liver injury; NA, not available.
Adapted from Björnsson ES, et al. Gastroenterology 2013;144:1419-
1425.e3, with permission from Elsevier.7
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Table 2. Common Medications Implicated in Drug Induced Liver Injury with Timing and Pattern of Injury
Drug Latency Pattern of injury
Antimicrobials
    Isoniazid 1–6 mo Hepatocellular, resembling viral hepatitis
    Rifampin 0–3 mo Hepatocellular, sometimes mixed
    Pyrazinamide 1–3 mo Hepatocellular, resembling viral hepatitis
    Amoxicillin-clavulanate 1–4 wk Cholestatic, more hepatocellular in children
    Sulfonamides 1–6 wk Cholestatic, sometimes mixed; immunoallergic
    Nitrofurantoin, minocycline 1 wk to months or years Both an acute and chronic injury form of injury seen. Immunoallergic, 
  autoimmune features
    Ketoconazole 0–3 mo Hepatocellular, sometimes mixed
Antiretrovirals
    NRTIs 1–6 mo Cholestatic or mixed with lactic acidosis (e.g., stavudine)
    nNRTIs 0–3 mo Initial hepatocellular evolving to cholestatic. Immunoallergic (e.g., nevirapine)
    Protease inhibitors 1–3 mo Hepatocellular, sometimes mixed (ritonavir)
Antiepileptics
    Phenytoin 0–3 mo Hepatocellular, cholestatic or mixed; immunoallergic
    Carbamezapine 1–3 mo Hepatocellular, cholestatic or mixed; immunoallergic
    Valproic acid 1–6 mo Hepatocellular or mixed, rise in ammonia, sometimes acidosis
Analgesics
    NSAIDs 1–6 mo Hepatocellular
Lipid lowering agents
    Statins 1–6 mo Hepatocellular, cholestatic or mixed; autoimmune
Immunologics 
    TNF antagonists 1–6 mo Hepatocellular, autoimmune
Herbal and dietary supplements
    Ephedra 1–3 mo Hepatocellular, resembling viral hepatitis
    Green tea extract 0–6 mo Hepatocellular
    Muscle enhancers 1–6 mo Cholestatic (anabolic steroids)
NRTIs, nucleoside reverse transcriptase inhibitors; nNRTIs, non-NRTIs; NSAIDs, nonsteroidal anti-inflammatory drugs; TNF, tumor necrosis factor. 
Table 3. Biopsy Reported Phenotypes of Drug Induced Liver Injury and Agents
Phenotype Histologic feature Example
Acute hepatic necrosis Collapse and centrolobular necrosis (Fig. 3) Acetaminophen, isoniazid
Acute fatty liver with lactic acidosis Microvesicular hepatic steatosis; 
  later with macrovesicular steatosis
Didanosine, valproate
Acute viral hepatitis like Inflammatory infiltrates Isoniazid, flutamide
Autoimmune-like hepatitis Plasma cell infiltration and interface hepatitis Minocycline, nitrofurantoin
Bland cholestasis Ballooned hepatocytes with minimal inflammation Anabolic steroids
Cholestatic hepatitis Ballooned hepatocytes with inflammation Amoxicillin-clavulanate, phenytoin
Cirrhosis Fibrosis without inflammation Methotrexate, amiodarone
Immunoallergic hepatitis Eosinophilic infiltration Phenytoin, trimethoprim-sulfamethoxazole 
Nodular regeneration Microscopic or macroscopic liver nodules without fibrosis Azathioprine, oxaliplatin
Nonalcoholic fatty liver Micro/macrosteatosis, ballooned hepatocytes, 
  periportal inflammation
Methotrexate, tamoxifen
Sinusoidal obstruction syndrome Obliteration of central veins with inflammation Busulfan
Vanishing bile duct syndrome Loss of small inter- and intralobular bile ducts (Fig. 1) Sulfonamides and β-lactams
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RUCAM does not clearly define “alcohol use.” It does not speci-
fy how much or how recent. Implicated agents that are “known 
hepatotoxins” are given points but the definition of what con-
stitutes a known hepatotoxin is not completely clear either. 
For example, it is not clear whether mere mention of elevated 
liver enzymes in a package insert as a rare side effect makes 
the agent a known hepatotoxin. Given these imprecisions, the 
RUCAM has a fairly low interobserver reliability (reliability 
coefficient of 0.51, upper 95% confidence limit 0.76).31 On the 
other hand, it is a useful starting point for the clinician, provid-
ing a framework for a diagnostic work-up and reminding one 
to think of cholestatic and hepatocellular injuries differently. It 
is also fairly accurate at the extreme categories (e.g., “unlikely” 
and “highly probable”).31 
Recently, the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) and National Library of Medicine (NLM) 
created LiverTox, an online, updated textbook for DILI (http://
www.livertox.nih.gov/). It contains over 750 agents with plans 
to expand to over 1,000. It has quickly become an invaluable 
resource with over 115,000 unique visitors per month.32,33 Infor-
mation is presented concisely, emphasizing incidence, clinical 
presentation and outcome. Direct links to a robust set of refer-
ences and illustrative cases are provided. Very commonly used 
medications are also included even if the risk of liver injury is 
quite low (e.g., omeprazole, ibuprofen, and amlodipine).
Clinical course and prognosis of DILI can be quite variable. 
Based on clinical experience, the late Hy Zimmerman, suggested 
a 10% mortality risk in DILI cases with the following: (1) aspar-
tate aminotransferase (AST) or ALT >3 times the ULN; (2) serum 
total bilirubin >2 times the ULN without elevation of alkaline 
phosphatase; and (3) no other reason for the rise in transami-
nases or bilirubin (absence of acute or CLD).34,35 Hy’s Law has 
proven remarkably robust, based on registries from the United 
States, Sweden, and Spain totaling about 1,500 patients.13,35,36 
Therefore, patients meeting these criteria need careful follow-up 
and consideration for early referral to a transplant center if any 
signs of hepatic decompensation arise (e.g., elevated interna-
tional normalized ratio (INR) and mental status changes). 
For the vast majority of cases (80%–90%), the prognosis for 
DILI is favorable with full recovery. In fact, DILI outcome was 
often viewed primarily as either fatal or having full recovery. 
However, recent data suggest that chronic DILI can occur in 
up to 10%–15% of cases. At the moment, there is no set diag-
nostic criteria, but it is broadly interpreted as persistent (>6–12 
months) elevations in liver enzymes despite cessation of the 
offending agent. Whether this is simply very slow to resolve 
injury, a true chronic immune mediated entity or superimposed 
background liver disease (e.g., nonalcoholic fatty liver disease) 
remains unknown. However, clear cases of severe chronicity 
such as vanishing bile duct syndrome (VBDS) are well described 
(Fig. 1).
SPECIFIC MEDICATIONS
We highlight the following classes of agents because they are 
commonly implicated in DILI and/or contain commonly pre-
scribed agents. For a more extensive list and coverage of agents, 
the reader is directed to other reviews, textbooks or LiverTox.37
1. Antimicrobials
Antimicrobials are by far the most commonly implicated 
drugs in DILI (45.5% of the cases in the U.S. DILIN registry, 
and 32% in the Spanish registry).13,36 β-Lactams make up the 
largest class of antibiotics prescribed in the United States.38 
and amoxicillin-clavulanate consistently tops the list of causal 
agents in DILI registries.13,36 The injury is felt to be from the 
clavulanate.39,40 The latency is usually between 2 and 6 weeks. 
The injury pattern is variable, with hepatocellular patterns more 
commonly seen in those under 55 years of age, and cholestatic/
mixed patterns in those over 55.11 There are also reports of im-
munoallergic reactions as well as VBDS.41,42 Other β-lactams im-
plicated include flucloxacillin and oxacillin (cholestasis) as well 
as cephalosporins.9,43,44
Antituberculosis drugs, including INH, rifampin, and pyra-
zinamide probably carry some of the highest DILI risk of any 
medication, but are less commonly prescribed compared to 
amoxicillin-clavulanate. Of the tuberculosis medications, INH 
has been the most studied. The mechanism has classically been 
thought to result from the toxic metabolite hydrazine, but more 
recent data suggest the injury is more complex including some 
immunoallergic component.45 INH causes asymptomatic trans-
aminase elevation in 20% of patients, symptomatic hepatitis 
Fig. 1. A native hepatectomy specimen from a 27-year-old male with 
vanishing bile duct syndrome due to allopurinol. This patient required 
liver transplantation 10 months after clinical presentation. A histolog-
ic section of the liver demonstrates a paucity of interlobular bile ducts. 
Two portal tracts shown here are devoid of interlobular bile ducts. 
Overall, approximately two-thirds of the small portal tracts showed 
bile duct loss (H&E stain, ×200). 
P, portal tract. 
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in 1% and severe injury in 0.01%.46 Injury resolves rapidly if 
the drug is held before onset of liver failure. For cases of mild 
injury, reintroduction of therapy has been done with success.47 
Rifampin typically will cause a mild hepatocellular injury pat-
tern. Pyrazinamide has a dose dependent hepatotoxic effect, and 
it has been shown to actually potentiate hepatotoxicity in INH-
rifampin combinations.48,49
Sulfonamides are another common antimicrobial implicated 
in DILI, with an incidence of hepatotoxicity approximated as 
high as 1 per 1,000 users.5 The pattern of injury is usually a 
cholestatic or mixed picture, with hypersensitivity symptoms 
(e.g., rash) being common. Indeed, DRESS is well described with 
this agent.24,50 VBDS has also been reported.51 Histology often 
confirms cholestasis with centrolobular hepatocyte swelling and 
bile accumulation (Fig. 2).
Hepatotoxicity from antifungals is well-described. The azoles 
(ketoconazole, fluconazole, itraconazole, and voriconazole) 
are particularly common culprits. Ketoconazole is perhaps the 
most notorious, with risk approaching 134 per 100,000 patient-
months.52 The pattern of injury is usually hepatocellular, with a 
latency of around a month.53 Fluconazole will usually cause a 
transient, asymptomatic rise of transaminases, with higher risk 
among bone marrow transplant patients.54,55 Cross reactivity 
between the azoles is unclear with some successful switches be-
ing reported. If such a switch is necessary careful monitoring of 
liver biochemistries is warranted.
DILI from antiretrovirals (ARVs) for treatment of human im-
munodeficiency virus infection has been well reviewed in the 
literature.56,57 Generally, ARVs are of four classes: nucleoside 
reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse 
transcriptase inhibitors (nNRTIs), protease inhibitors (PIs), and 
integrase inhibitors. NRTIs tend to cause mitochondrial injury, 
leading to microvascular steatosis with lactic acidosis. Despite 
severe injury (e.g., jaundice and coagulopathy), elevation in 
transaminases can be relatively modest. nNRTIs can induce a 
hypersensitivity reaction, with fever, eosinophilia and rash. PI 
hepatotoxicity is uncommon, but acute hepatitis, rarely lead-
ing to ALF has been reported with ritonavir.58 Risk of DILI from 
ritonavir is higher at full dosage compared to lower dosing. 
Otherwise, PIs are known to induce asymptomatic hyperbiliru-
binemia secondary to inhibition of uridine diphosphate gluc-
uronosyl transferase, inducing a clinical Gilbert’s syndrome.59 
Integrase inhibitors are newer to ARV therapy, and relatively 
little hepatotoxicity has been reported.
2. Antiepileptics
Phenytoin can induce an asymptomatic elevation of 
γ-glutamyl transferase and alkaline phosphatase. However, more 
severe hepatocellular or cholestatic hepatitis and hypersensitivi-
ty reactions including DRESS are well described.60,61 Phenytoin’s 
aromatic ring structure is similar to that found in carbamezap-
ine which can cause similar hepatotoxicity presentations.60 Thus 
it recommended that both agents be avoided when such DILI 
occurs. Indeed, phenobarbital, lamotrigine and ethosuximide 
also carry similar aromatic ring structures and probably carry 
some cross-reactivity risk as well. Switching to levetiracetam, or 
gabapentin may be safer.
Valproic acid, a nonaromatic antiepileptic, is the most com-
mon antiepileptic causing DILI in the United States.13 It is 
unique in that it can lead to three different hepatotoxicity 
presentations: (1) hyperammonemic encephalopathy or coma 
with relatively modest liver enzyme abnormalities; (2) acute he-
patocellular injury; and (3) Reye’s like picture, reported usually 
in children.33 Histology typically suggests mitochondrial injury 
with microvesicular steatosis and variable inflammation or ne-
crosis.24,62
3. Nonsteroidal anti-inflammatory drugs
Although much less common than acetaminophen liver in-
jury, nonsteroidal anti-inflammatory drugs (NSAIDs) do pose a 
hepatotoxicity risk that is frequently overlooked, particularly in 
women and the elderly.63,64 Given the diverse chemical structures 
of NSAIDs, the pattern of injury and risk are variable. Ibupro-
fen rarely causes significant hepatotoxicity, but because of its 
widespread use, it was a common agent reported in the Spanish 
registry.36 However, population incidence is probably quite low 
(1.6 per 100,000).65 Clinical presentations vary, including as-
ymptomatic elevation in ALT and AST, acute hepatitis, ALF, and 
VBDS.66,67 Diclofenac, the most commonly prescribed NSAID, 
carries a higher risk of DILI, with an estimated incidence as high 
Fig. 2. A liver biopsy from a 69-year-old male patient with a choles-
tatic pattern of liver injury following administration of trimethoprim-
sulfamethoxazole. The hepatic lobules showed predominantly cen-
trizonal hepatocanalicular cholestasis and marked swelling of the 
perivenular hepatocytes. In this case, there was no evidence of ongo-
ing significant biliary epithelial injury in the portal tracts (inset). The 
antibiotic had been held for several weeks. A biopsy was conducted 
for persistent jaundice and pruritus. Eventually, the patient had a full 
recovery (H&E stain, ×200). 
C, central vein. 
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as 1 per 9,148 users.7 It typically induces an acute hepatocel-
lular or mixed injury pattern, with some cases of an AIH-like 
presentation.68 The mechanism of injury is thought to be from 
metabolites (diclofenac acyl glucuronide and diclofenac-2,5-
quinone imine) causing direct cellular damage or autoimmu-
nity.69 Cyclooxygenase 2 inhibitors (i.e., celecoxib) did not show 
significantly more liver enzyme elevation than placebo in clini-
cal trials. Nevertheless, rare cases of acute cholestatic hepatitis 
and need of liver transplant are reported.70,71
4. Statins
Much has been written about statin hepatotoxicity and in 
many ways, this class is one of the best examples of the diffi-
culties in balancing benefit and risk when it comes to DILI. The 
statin benefit in such an important health threat as cardiovas-
cular disease makes their long-term use widespread and highly 
recommended. Yet rare instances of hepatotoxicity raise con-
cerns for patients, clinicians and the pharmaceutical industry, 
and this benefit versus risk tension is unlikely to go away. Mon-
itoring liver enzymes is often done, but largely unsupported by 
data. In fact, the frequency of liver injury in statin exposure is 
estimated at 1 in 100,000 patient-years.72 About 3% of patients 
taking a statin will develop a rise in transaminases, but these 
will typically normalize with continued use.72,73 Multiple studies 
have demonstrated statin safety in patients with chronic liver 
disease and they should not be withheld from these patients, 
particularly in those where the cardiovascular benefit heavily 
outweighs the risk of DILI (e.g., NAFLD patients).74,75 Neverthe-
less statins can cause a spectrum of liver injury (cholestatic and 
hepatocellular) which can rarely be severe or fatal (Fig. 3).76-79 
A better means of identifying those rare injuries early on and 
those at risk for DILI from these commonly used and needed 
agents is clearly needed.
5. Antagonists of tumor necrosis factor
Antagonists of tumor necrosis factor (aTNFs; infliximab, 
adalimumab, and certoluzimab) have become a mainstay in the 
treatment of inflammatory bowel disease (IBD) and rheumatoid 
arthritis. There are two liver injury issues with aTNFs: reactiva-
tion of underlying chronic hepatitis B and direct hepatotoxicity. 
Screening for hepatitis B virus (HBV) infection is recommended. 
If hepatitis B surface antigen (HBsAg) is positive then prophy-
lactic therapy with oral HBV medications should be given.80,81 
If HBsAg is negative but antihepatitis B core antibody is posi-
tive (i.e., past exposure), then monitoring is recommended, with 
prompt application of HBV therapy if reactivation occurs.
While all the aTNFs can cause hepatotoxicity, infliximab 
was most frequently cited in the U.S. DILIN case series.82 The 
presentation varies including acute hepatitis, bland cholestasis, 
autoimmune-like injury and ALF.24,82 Interestingly, there are 
reports of safely transitioning from infliximab to etanercept in 
rheumatoid arthritis and infliximab to adalimumab in IBD.83-85 
This may be due to fundamental differences in protein structure, 
as etanercept is made of soluble TNF-α receptors linked to the 
Fc portion of human IgG1. Infliximab is a humanized mouse 
monoclonal IgG1 antibody, and adalimumab is a fully human 
monoclonal IgG1 antibody.82 
6. Herbal and dietary supplements
HDS use has grown steadily with 54% of U.S. adults using 
them by 2006 versus 40% between 1988 and 1994.86 The true 
incidence of hepatotoxicity from any particular HDS is impos-
sible to estimate, as the total population of patients using the 
agent is unknown and there are no prescription numbers to 
monitor. However, the U.S. DILIN recently reported an increase 
in the percentage of HDS cases from 7% to 20% over 9 years.87 
We will mention just a few remarkable HDS hepatotoxicities 
to highlight some of the clinical features as well as challenges. 
More comprehensive reviews are published.88,89 
With the rise in obesity, there is a growing market for weight 
loss supplements. Ma-Huang (Ephedra sinica), a Chinese herbal, 
is commonly taken for weight loss. Such products can cause a 
hepatitis with autoimmune features, sometimes with massive 
necrosis leading to ALF.88,90,91 Ephedra was felt to be the causal 
component, and in 2004, the Food and Drug Administration 
prohibited the sale of ephedra containing products. However, 
this ban has occasionally been circumvented.92 
Green tea or Camellia sinensis extracts has been marketed as 
“ephedra free” alternative in weight loss supplements. However, 
the catechins and their gallic acid esters in such extracts can 
cause oxidative stress in the liver.88,89,93 The pattern of injury is 
typically hepatocellular, however, there are reports of mixed 
injury and AIH.94-96 Camellia Sinensis continues to be a major 
c
Fig. 3. A liver biopsy from a 55-year-old female who developed a 
submassive hepatocyte necrosis and dropout 2 to 3 months after 
starting rosuvastatin. This photomicrograph shows large areas of 
hepatocyte dropout with multiple aggregates of reactive ceroid-laden 
macrophages (arrows). No viable hepatocytes are present in this pic-
ture (H&E stain, ×200). 
C, central vein; P, portal tract. 
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component of many weight loss supplements sold in the United 
States today.97
Muscle enhancers are frequently implicated in liver injury 
particularly those containing anabolic steroids.87,98 By the time 
most patients present, they typically have a bland cholestatic 
pattern of injury (high bilirubin with relatively low liver en-
zymes) occurring within 6 months of starting therapy.24 Deep 
jaundice (e.g., bilirubin over 20 mg/dL) can occur with weight 
loss, nausea, and pruritus that can last for months. The vast 
majority of cases recover, but cases of chronic ductopenia have 
been reported.99,100 Additionally, anabolic steroids are linked to 
tumors of the liver, particularly hepatic adenomas.101 
FUTURE DIRECTIONS
DILI research is poised to make significant discoveries that 
will translate to clinical practice over the next decade. Sev-
eral DILI registries are now growing and maturing worldwide. 
They will provide rich repositories for translational and clinical 
research. Based on the clinical data alone in these registries, 
newer diagnostic algorithms to improve upon the RUCAM will 
be forthcoming. Consolidation of large medical groups and sys-
tems in the United States along with the use of large electronic 
medical records (EMR) will provide a rich data source for phar-
macoepidemiologic studies that will help define incidence and 
risk factors. Such “big data” EMRs may also identify cases for 
enrollment in studies. With increasing availability of tissue and 
blood from well-defined DILI cases, the chance of identifying 
biomarkers for DILI diagnosis and risk will increase. Already, 
genome-wide association studies (GWAS) are providing insight 
into DILI pathophysiology. Several HLA associations with DILI 
from a variety of agents strongly suggests an immune compo-
nent to the injury.102-105 Such immune components may lend 
themselves to targeted therapies which may truncate DILI and 
prevent ALF. Other genetic and drug metabolism markers also 
show promise. Right now, none of the GWAS associations are 
common or specific enough for clinical use, but next generation 
sequencing technology and increasing sample sizes will bring 
some markers to diagnostic testing and risk assessment in the 
years to come.106,107
CONCLUSIONS
DILI remains a clinical challenge. Its iatrogenic nature and 
potential for severe or fatal outcome can be unnerving for clini-
cian and patient alike. While relatively uncommon to rare for 
any specific agent, the overall incidence may be higher than 
previously thought and will probably rise with the aging of the 
general population and increasing polypharmacy. Useful diag-
nostic biomarkers will be forthcoming, but for now, diagnosis 
hinges on good old-fashioned history taking and efficient ex-
clusion of competing diagnoses. Being aware of commonly im-
plicated agents, their patterns of injury, and diagnostic resources 
(e.g., LiverTox and RUCAM) are also essential. The risks of ALF 
and chronicity require vigilant follow-up once the diagnosis has 
been made.
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